1 Under-the-Radar Stock Riding the AI Boom (Hint: It's Not Nvidia)

Amkor said first-quarter revenue rose 27% year over year to a record $1.68 billion, with AI data center revenue also hitting a record. The company signed a 10-year agreement with TSMC for advanced packaging and testing in Arizona, supporting a multi-year capacity expansion plan, but shares have already more than doubled this year and trade near 50x earnings. Management guided Q2 revenue to $1.75 billion-$1.85 billion and expects 2026 capex of $2.5 billion-$3.0 billion, highlighting both growth momentum and execution risk.

Analysis

AMKR is no longer being valued as a dull OSAT; the market is pricing it as a scarce bottleneck asset in the AI stack. The key second-order effect is that packaging capacity, not just wafer capacity, becomes the gating item for scaling high-end compute, which should keep pricing power and utilization high for the few vendors that can qualify with top-tier customers. That said, the TSMC agreement also signals that the ecosystem is beginning to dual-source geographically, which is bullish for supply-chain resilience but could cap AMKR's ability to extract monopoly-like returns over time.

The real fundamental swing factor is not near-term revenue, but whether capex converts into structurally higher mix before the market gets impatient. With a large spend wave hitting before Arizona revenue arrives, the next 12-18 months likely feature margin dilution and elevated execution variance, even if demand stays strong. The stock’s multiple leaves little room for schedule slips, customer qualification delays, or a softer AI capex cycle; in cyclical semis, the market tends to punish even modest timing misses once expectations are elevated.

Consensus seems to be underestimating how much of AMKR’s upside is already pulled forward by the rerating, while underestimating how valuable the adjacent beneficiaries may be. TSM benefits by de-risking its supply chain, while AAPL and NVDA get a more credible U.S.-based packaging path, which could matter if trade policy or export constraints tighten. The contrarian setup is that AMKR may be the right business but the wrong entry point: the thesis is sound over 2-3 years, but the near-term asymmetry now favors waiting for a post-capex or execution-related drawdown rather than paying peak optimism today.

Key Decisions for Investors

• Avoid initiating a fresh outright long in AMKR here; if already long, consider trimming 25-33% and retaining the core for the 2027-2028 packaging monetization window.
• Buy AMKR on a pullback toward a lower-teens forward multiple compression event or any sign of Arizona schedule slippage; the better entry is a 10-15% correction, not momentum-chasing.
• Pair trade: long TSM / short AMKR for the next 6-12 months if you want AI packaging exposure with less execution risk; TSM gets supply-chain optionality without the same capex-margin overhang.
• If expressing bullishness, use call spreads on AMKR 9-12 months out rather than stock; upside is real, but the stock is vulnerable to a de-rating if 2027 start-up costs get re-anchored higher.
• Keep NVDA and AAPL on watch for indirect beneficiaries of U.S.-based advanced packaging capacity; any confirmation of qualification progress could support relative outperformance versus the broader semiconductor group.